Targeted oncology focus Early-stage biotechnology startup focused on next generation targeted anti-cancer therapies, presenting opportunities to align with pharma partners pursuing precision medicine and combination regimens in hard-to-treat cancers such as pancreatic, lung, and ovarian cancer.

Clinical development potential Small team with ongoing research programs and leadership additions; potential for collaboration on preclinical data generation, translational research, and accelerated partnerships to de-risk early-stage programs.

Advisory and leadership access Recent hires and board appointments signal a growing governance and scientific guidance network, offering BD leverage points for co-development deals, strategic investments, or joint ventures with larger biotech entities.

Funding and milestones Current funding under $2M and revenue under $1M indicate a runway reliant on partnerships; ideal for strategic licensing, milestone-based collaborations, and upstream oncology platform licensing discussions.

Technology and IP alignment Platform emphasis on protein-based nano-formulations with established anticancer mechanisms suggests fit with CROs, contract development, and tech transfer opportunities to larger biotechs seeking novel targeted delivery capabilities.